title: The effect of patient size and dose of recombinant human erythropoietin therapy on red blood cell volume expansion in autologous blood donors for elective orthopedic operation.
abstract: BACKGROUND
  Recombinant human erythropoietin (EPO) therapy has been known to enhance erythropoiesis and facilitate autologous blood donation before elective orthopedic operations. However, the optimal EPO dose in this setting remains undefined. To help determine this, we have examined the effect of patient weight and EPO dose on red blood cell (RBC) volume expansion.
  
  
  METHODS
  Forty-six nonanemic autologous blood donors enrolled at our institution in two previously reported multicenter clinical trials were analyzed. Patients received either placebo or EPO (150, 300, or 600 units [U] per kg) given intravenously at each of six AB blood type donation visits.
  
  
  RESULTS
  Total preoperative RBC volume expansion over a 22 day period was 465 +/- 135 mL (mean +/- SD) in patients receiving a placebo and 588 +/- 201 mL, 735 +/- 144 mL, and 881 +/- 292 mL in patients receiving graded concentrations of EPO. When RBC volume increase was corrected for patient weight and EPO dose, patients receiving placebo or EPO (150, 300, and 600 U per kg) expanded RBC volume by 5.9 mL per kg in patients receiving placebo and 7.9, 9.1, and 10.9 mL per kg in patients receiving EPO, respectively (p < 0.02 for each EPO group compared with placebo group). A direct relationship between EPO dose and RBC volume increase (response) over 22 days was determined by the linear regression equation: RBC volume (mL per kg) = 6.34 + 0.0013X, r = 0.98, where X equals total units EPO administered (per kg body weight).
  
  
  CONCLUSIONS
  We conclude that EPO dose can be based on anticipated blood losses and transfusion needs in autologous blood donors before orthopedic operation.
authors.affiliation: Department of Medicine, Washington University School of Medicine, St. Louis, MO.
authors.forename: L T
authors.initials: LT
authors.lastname: Goodnough
authors.forename: D
authors.initials: D
authors.lastname: Verbrugge
authors.forename: R E
authors.initials: RE
authors.lastname: Marcus
authors.forename: V
authors.initials: V
authors.lastname: Goldberg
mesh_terms: D000368:Aged; D001782:Blood Donors; D001804:Blood Transfusion, Autologous; D001810:Blood Volume / Q000187:drug effects; D001835:Body Weight; D001842:Bone and Bones / Q000601:surgery*; D004305:Dose-Response Relationship, Drug; D017558:Elective Surgical Procedures; D004911:Erythrocyte Volume / Q000187:drug effects*; D004921:Erythropoietin / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005293:Ferritins / Q000097:blood; D006400:Hematocrit; D006801:Humans; D007275:Injections, Intravenous; D007501:Iron / Q000097:blood; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011994:Recombinant Proteins
chemical_list: D010919:Placebos; D011994:Recombinant Proteins; D004921:Erythropoietin; D005293:Ferritins; D007501:Iron